3 Reasons to Avoid Shares of Valeant Pharmaceuticals

The company has done everything right over the past five years. But this may not be a bet worth taking.

The Motley Fool

Over the past five years, few Canadian stocks have been on as nice a run as Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX). Since this time in 2009, the stock has returned over 60% per year to shareholders. The company is undeniably the darling of the Canadian healthcare sector.

On Thursday morning, the company again reported strong results. Cash earnings came in at $1.72 per share, up 35% year-over-year. Revenue jumped by 77% to $1.89 billion.

Furthermore, Valeant is confident it can succeed in its $50 billion takeover attempt of Allergan (NYSE: AGN), best known for anti-wrinkle treatment Botox. Given Valeant CEO Michael Pearson’s track record of great acquisitions, this would also likely be great news for shareholders. And in this case Mr. Pearson even has the endorsement of activist investor Bill Ackman.

But before you buy Valeant’s shares, there are some things you must consider. Below are the top three reasons to steer clear of Valeant stock.

1. Uncertainty

Valeant’s business model rests on making numerous acquisitions to fill its pipeline, something that the company has done very well thus far. But this means the future is always very uncertain for the company. What happens if no suitable targets can be found? Will Mr. Pearson still feel the need to act? Analysts routinely say that Valeant is the most difficult stock to make projections for.

Valeant’s stock currently trades at just over $140 per share, which is an expensive price, considering the company made less than $7 in cash earnings per share in 2013. The market is clearly pricing in future successful acquisitions. So this makes Valeant much more speculative than most stocks on the TSX.

2. Accounting issues

Valeant’s acquisitive business model naturally leads to accounting discrepancies. For example, the company hardly needs to spend any money at all on research and development, leading to margins that appear high.

Furthermore, many of the accounting measures that Valeant presents are adjusted numbers, rather than standard accounting figures. More specifically, measures such as adjusted operating cash flow and cash earnings per share strip out certain acquisition-related costs, even though these costs are a central part of the company’s business model.

To be clear, there is nothing fraudulent about these numbers. But it does require an extra level of caution and scrutiny from investors.

3. Other alternatives

Owning shares of Valeant is akin to handing money over to Mr. Pearson, and trusting him to spend it wisely. So far he has. But there are other companies that have just as good a track record. The best example in Canada is Constellation Software, where CEO Mark Leonard has an excellent track record of buying small software companies.

I am not saying that Valeant shares will go down, or even that they’re overpriced. But they are very speculative, and buying the shares is a bet simply not worth taking when there are so many great alternatives.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair holds no positions in any of the stocks mentioned in this article. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »